Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
The review found no eligible studies for this question.
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes recurrence compared with intravesically administered BCG alone (very low certainty).
The review found no eligible studies for this question.
Intravesically administered BCG combined with IFN‐α showed no clear difference in progression compared with intravesically administered BCG alone (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes disease‐specific mortality compared with intravesically administered BCG alone (very low certainty).
The review found no eligible studies for this question.
Intravesically administered BCG alternating with IFN‐α may leads to higher time‐to‐recurrence compared with intravesically administered BCG alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in time‐to‐progression compared with intravesically administered BCG alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in disease‐specific mortality compared with intravesically administered BCG alone (low certainty).